ATAI Stock Analysis: Buy, Sell, or Hold?
ATAI - ATAI Life Sciences N.V. Common Shares
$7.35
0.06 (0.82%)
â˛
5d:
+0.0%
30d:
+1.94%
90d:
+94.44%
WAIT
LOW Confidence
Analysis Updated: Sep 10, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 4, 2026 at $7.33 · last confirmed Sep 10, 2026
Strength: 4.7/10
Get Alerted When ATAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ATAI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ATAI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ATAI is currently trading at $7.35, which is considered slightly high relative to its 30-day fair value range of $7.23 to $7.38.
Technical Outlook: Technically, ATAI is in a strong uptrend. The price is currently testing key support at $7.23. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ATAI scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.10 (+10.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATAI is in a strong uptrend. The price is currently testing key support at $7.23. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ATAI scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.10 (+10.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$7.23 -
$7.38
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
39.5%
All Signals
- BEARISH: Weak technical setup (29/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($8.10)
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.23 -
$7.38
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$7.23
Resistance Level
$7.43
Current Trend
Strong Uptrend
Technical data as of
Sep 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-15.00
Wall Street Target
$8.10
(+10.2%)
Revenue Growth (YoY)
137.0%
Earnings Growth (YoY)
-96.8%
Share & Embed Analysis
Last updated: September 13, 2026 3:57 AM ET
Data refreshes hourly during market hours. Next update: 4:57 AM
Data refreshes hourly during market hours. Next update: 4:57 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Kevin James Craig
SELL
42579 shares
2026-04-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
